INTRODUÇÃO: Relatos conflitantes têm dificultado para se estabelecer o potencial benefício da glutamina (GLN) no tratamento de condições inflamatórias agudas. Nós avaliamos o efeito da infusão parenteral de GLN, prévia à pancreatite aguda (PA) experimental, nos mediadores inflamatórios, morbidade e mortalidade. MÉTODOS: Ratos Lewis (n = 131) receberam glutamina parenteral (grupo GG), solução salina (grupo SS ou controle), ou permaneceram sem infusão parenteral (grupo Sham) por 48h. Após este período, foi induzida PA por meio da injecção retrógrada de taurocolato de sódio no ducto pancreático. Sangue, amostras de pulmão, fígado, pâncreas e líquido ascítico foram colhidos a partir de 2, 12 e 24 horas após PA para avaliação das variáveis propostas (citocinas, hsp, histologia, amilase). Sessenta animais permaneceram vivos após PA para a análise da mortalidade em sete dias. RESULTADOS: A análise entre grupos não mostrou diferenças significativas nos níveis de citocinas (p > 0,05). Análise cinética dentro de cada grupo ao longo do tempo mostrou maior INF-y no grupo Sham e SS às 2h do que em 12h e 24h, maior IL-2 e inferior IL-10 no Sham, às 24h do que em 2h e 12h, e menor IL-10 no SS e GG em 24 h do que no tempo de 2h (p <= 0.05). O grupo GG exibiu maior expressão de HSP 90 no pulmão e no fígado do que no grupo Sham nos tempos de 2h e 12h, respectivamente; e maior expressão no fígado de HSP90 e HSP70 no grupo SS no tempo 12 horas (p < 0,01). O grupo Sham apresentou maior expressão de HSP 70 no pulmão e HSP 90 no fígado do que os outros grupos no tempo de 24h. Não ocorreram alterações na taxa de mortalidade. CONCLUSÕES: Em modelo de PA experimental induzida por taurocolato de sódio, o pré-tratamento com GLN parenteral melhorou o perfil dos mediadores inflamatórios, sem afetar a mortalidade / INTRODUCTION: Conflicting reports have hindered establish the potential glutamine (GLN) benefit in treating acute inflammatory conditions. We evaluated the effect of parenteral GLN infusion before experimental acute pancreatitis (AP), as systemic inflammation-reproducing model, on inflammatory mediators and mortality. METHODS: Lewis rats (n=131) received parenteral glutamine (GG group), saline (SS or Control group), or remained without parenteral infusion ( Sham group) for 48h. Thereafter, AP was induced by retrograde injection of sodium taurocholate into pancreatic duct. Blood, lung, liver and pancreas samples were collected from 2, 12 and 24h post-AP to assess serum cytokines levels, tissue HSP expression, histology and amylase. Sixty animals remained alive post-PA for seven-day mortality analysis. RESULTS: Punctual between-groups analysis did not show differences in cytokine levels (p > 0.05). Intragroup analysis over time showed higher INF-y in Sham and SS at 2h than at 12h and 24h, higher IL-2 and lower IL-10 in Sham at 24h than at 2h and 12h, and lower IL-10 in SS and GG at 24h than at 2h timepoint (p <= 0.05). GG group exhibited higher lung and liver HSP90 than Sham at 2h and 12h timepoints, respectively; and higher liver HSP90 and HSP70 than SS at 12h timepoint (p < 0.01). Sham group presented higher lung HSP70 and liver HSP90 than the others at 24h timepoint (p < 0.02). No changes occurred on mortality rate. CONCLUSIONS: In sodium taurocholate-induced PA model, pretreatment with parenteral GLN improved inflammatory mediator\'s profile, without affecting mortality

A Síndrome do Intestino Curto (SIC) é uma doença complexa que ocorre após extensa ressecção do intestino delgado, levando a uma má absorção de nutrientes e fluidos, uma condição que pode causar diarreia, desnutrição e perda de peso graves com alto risco para o desenvolvimento da osteoporose. Estudos recentes mostram existir ampla interação fisiológica do esqueleto com os diversos sistemas, incluindo o metabolismo energético e o trato digestório. Peptídeos originados não só no tecido adiposo, mas também no intestino como as incretinas [GIP (polipeptídeo trópico insulínico dependente de glicose) e GLP1 (peptídeo 1 tipo glucagon)] modulam a atividade de remodelação óssea. O objetivo principal do atual estudo foi avaliar a relação entre os tecidos adiposos subcutâneo (TAS), visceral (TAV), lipídeos intra-hepáticos (LIH), tecido adiposo da medula óssea (TAMO), bem como do GIP, GLP1, e grelina com a densidade mineral óssea (DMO) em pacientes com SIC. Tratase de um estudo observacional prospectivo composto por dois grupos experimentais pareados por altura, idade e sexo: a) o grupo controle (GC) (n = 18; 9M,9F) e b) o grupo de pacientes com SIC, o qual foi avaliado em 2 ocasiões, com intervalo de um ano entre as análises, sendo denominados SIC0 (n = 14; 7M,7F) e SIC1 (n = 11; 6M,5F). Em comparação com o GC, pacientes com SIC ao longo do estudo apresentaram menor DMO e maior LIH e GIP (p< 0,05). Os valores de TAMO, GLP1 e grelina foram similares entre os grupos. O TAMO teve correlação negativa e significativa com DMO de L3 no GC (r= -0,6; p< 0,05), porém, no grupo SIC esta correlação foi positiva, mas sem significância estatística ao longo do estudo: SIC0 (r= 0,45; p= 0,13) e SIC1 (r= 0,45; p= 0,17). LIH associou-se negativamente com DMO do colo do fêmur (R²= 0,16; p< 0,05) e quadril total (R²= 0,27; p< 0,05). Existe alta prevalência de osteoporose em pacientes com SIC. No entanto, não se observou nem expansão de TAMO e nem relação negativa da DMO com o TAMO. O acesso a calorias parece afetar positivamente a relação entre TAMO e massa óssea. A deposição hepática de lipídeos parece afetar negativamente a massa óssea de pacientes com SIC. / Short bowel syndrome (SBS) is a complex disease that occurs after extensive resection of the small intestine leading to malabsorption of nutrients and fluids, a condition that can cause severe watery diarrhea, dehydration and acute weight loss, developing high risk for the appearance of osteometabolic disease. Studies have shown the progress on the physiological interaction of the skeleton with the various systems, including energetic metabolism and the gastrointestinal tract. Peptides originated not only in adipose tissue but also in the intestine such as incretin [GIP (Glucose-dependent insulinotropic polypeptide) and GLP1 (glucagonlike peptide 1) modulate bone remodeling activity. The main objective of the current study was to evaluate the influence of subcutaneous (SAT), visceral (VAT) adipose tissue, intrahepatic lipids (IHL), bone marrow fat adipose tissue (MAT), as well as the influence of GIP, GLP1, and ghrelin on the bone mineral density (BMD) of SBS patients. It is a prospective observational study composed by two experimental groups matched by height, age and sex: a) the control group (CG) (n = 18; 9M,9F) and b) the SBS group which were evaluated in two occasions with a period between analyzes of one year: named SBS0 (n = 14; 7M,7F) and SBS1 (n = 11; 6M,5F). Compared to CG, SBS patients throughout the study had significantly lower BMD and elevated IHL and GIP (p< 0.05). Values of MAT, GLP1 and ghrelin were similar between groups. MAT was negatively and significantly correlated with L3 BMD in the CG (r = -0.6; p< 0.05) and positively correlated, but not significant with L3 BMD in the SBS group throughout the study: SBS0 (r= 0.45; p= 0.13) and SBS1 (r= 0.45; p= 0.17). IHL was negatively and significantly associated with femoral neck BMD (R²= 0.16; p< 0.05) and total hip BMD (R²= 0.27; p< 0.05). The occurrence of osteoporosis is frequent in SBS patients, but MAT is not increased in these patients and had positive correlation with BMD, although not significant. Access to calories seems to positively affect the relationship between MAT and bone mass. IHL appear to negatively affect bone mass in SBS patients.

L'augmentation de la survie des grands prématurés fait de la réduction des séquelles dans cette population un enjeu majeur. Alors qu'il influence leur devenir, le support nutritionnel des grands prématurés échoue souvent à prévenir le déficit protéino-énergétique, les carences nutritionnelles, et les ralentissements de croissance, aggravant leur pronostic. Nos recherches investiguaient plusieurs axes des stratégies nutritionnelles actuelles, leurs limites ainsi que les perspectives d'améliorations : I) parentérales, II) entérales, III) préventions des complications, IV) évaluation de la croissance. Il s'agissait d'un ensemble d'études cliniques, qui révélaient : I) Des variations significatives d'apports parentéraux à l'intérieur des centres, ainsi qu'une sous-utilisation des lipides, participant au déficit protéino-énergétique précoce. Un impact des lipides sur la croissance, le développement cérébral, voire l'incidence de complications était suggéré. II) Des avantages de l'utilisation de lait maternel frais dans la 1ère semaine de vie sur la poursuite de l'allaitement des nouveau-nés hospitalisés, ainsi que des variations importantes de sa composition. Une augmentation des taux d'allaitement sur les périodes d'études révélait un effet bénéfique de la recherche, même « observationnelle », sur l'allaitement. III) Une augmentation du risque d'hyperglycémie en cas de diminution de la phosphatémie. IV) Des répercussions modérées de la restriction de croissance intra-utérine sur le neuro-développement des prématurés, malgré des réserves auxologiques. Ces travaux permettaient donc d'identifier plusieurs barrières, et d'envisager différentes stratégies d'amélioration du soutien nutritionnel. Ils soulignent la complexité et l'importance des liens entre nutrition, croissance et développement neurologique des enfants à risques. Des efforts supplémentaires sont nécessaires pour optimiser les connaissances, les recommandations et les pratiques dans ce domaine / Facing to increasing survival of very preterm neonates, reducing sequelae in this population became a major public issue. Nutritional support of preterm neonates has a durable impact on their future. However, it often fails to prevent the protein-energetic imbalance, nutritional deficiencies, and post-natal growth restriction, which act as aggravating factors. Our researches evaluated different axes of current nutritional strategies, limitations and possible improvements: I) parenteral, II) enteral, III) prevention of complications, IV) growth assessment. Most relevant findings of these clinical studies were: I) Significant variations of parenteral intakes in the centres, as well as inadequate use of lipids, involved in early energetic-protein deficit. Impact of lipids on growth, brain development, and even the incidence of complications were suggested. II) Advantages in using fresh raw mother's own milk in the early days to enhance breastfeeding in hospitalized neonates, as well as important changes in mother's milk composition. An increase in breastfeeding rates over the periods of studies showed a beneficial effect of the research, although "observational", on breastfeeding. III) An increased risk of hyperglycemia in case of low phosphatemia. IV) A moderate impact of being small for gestational age on neuro-development in a preterm cohort, and related auxologic limitations. This work allowed to recognize some barriers of the nutritional support, and to consider different improvement strategies. It emphasizes the close and important links between nutrition, growth and neurological development of vulnerable infants. Further efforts are needed to optimize knowledge, recommendations and practices in this area

SMOFLipid® is a commonly used fat emulsion for parenteral nutrition. We investigated how enrichment of SMOFLipid® with n-3 polyunsaturated fatty acids (PUFA) in a form of second fat emulsion, Omegaven® , changes fatty acid composition of total plasma phospholipids and erythrocyte phospholipids, cytokine concentrations in serum and in supernatant from in vitro whole blood culture stimulated with lipopolasaccharide (LPS) and we evaluated also changes in oxido- reductive balance. Eight patients on long-term home parenteral nutrition recieved both emulsions, SMOFLipid® (6 weeks) and SMOFLipid® +Omegaven® (4 weeks), one by one. We observed no significant differences in common laboratory and clinical parameters between these two types of diet. Enrichment of SMOFLipid® with Omegaven® led to an increase in eicosapentaenoic (EPA) and docosahexaenoic acid (DHA) in total plasma phospholipids and there was also an increse in proportion of EPA in erythrocyte phospholipids, while proportion of DHA remained unchanged. These changes were in both phospholipids of plasma and erythrocyte compensated for a decrease in proportion of linoleic and arachidonic acid (n-6 PUFA). There were elevated IL-6 and TNF-α serum concentrations in patients after both diets. There was a decrease in IL-6 production by 36% with SMOFLipid®...

Cadre conceptuel et problématique : La cholestase hépatique est une pathologie à large éventail d’étiologies, affectant fréquemment les nouveau-nés. Un diagnostic approprié est essentiel pour la prise en charge clinique, le choix des traitements et l’amélioration du pronostic. Alors que les prématurés ont un risque accru de développement de la cholestase, les algorithmes de traitement ne proposent qu’une prise en charge unique, quel que soit l’âge gestationnel (AG) du patient. Objectif : Déterminer si le profil clinique, la prise en charge et le pronostic de la cholestase néonatale diffèrent selon l’AG. Méthodologie : Une étude de cohorte rétrospective de nouveau-nés atteints de cholestase et admis en néonatologie au CHU Sainte Justine entre janvier 2014 et décembre 2017 a été menée. La cholestase était définie par au moins deux valeurs consécutives de bilirubine conjuguée ≥ 34 μmol/L. La cohorte a été stratifiée en deux groupes d’AG : les extrêmes et les grands prématurés (< 32 semaines AG) et les prématurés modérés ou tardifs et naissances à terme (≥ 32 semaines AG). Résultats : 125 nouveau-nés sur 3 277 ont développé une cholestase. L’incidence globale était de 4% ; cette incidence était 5 fois plus élevée chez les nouveau-nés < 32 semaines d’AG comparativement aux ≥ 32 semaines d’AG. La cholestase était associée à une nutrition parentérale chez 91% des patients avec AG < 32 semaines et seulement 40% des patients avec AG ≥ 32 semaines (p < 0,01). Alors que l'acide ursodésoxycholique était plus prescrit aux nouveau-nés ≥ 32 semaines AG, les émulsions lipidiques à base d'huile de poisson étaient plus administrées aux nouveau-nés < 32 semaines AG, parmi les patients recevant une nutrition parentérale. Conclusion : La cholestase néonatale est associée à deux profils cliniques différents, basés sur l'AG. Nous recommandons que les tests diagnostics et la prise en charge clinique de la cholestase soient adaptés à l'AG. Une nouvelle approche pour l'évaluation d'un nourrisson atteint d'hyperbilirubinémie conjuguée est proposée. / Background and Aims: Cholestasis is a frequent neonatal disease that has a wide range of etiologies. Appropriate diagnosis is essential to clinical management, treatment choices and improvement of outcomes. Most references discuss neonatal cholestasis as one entity. The goal of this study was to determine if the clinical profile, management and outcome of cholestasis differ according to gestational age (GA). Methods: Medical records of infants with cholestasis in the division of neonatology at CHU Sainte Justine, between January 2014 and December 2017, were retrospectively reviewed. Cholestasis was defined as two or more consecutive conjugated bilirubin values ≥ 34μmol/L. The cohort was stratified into two groups: extremely to very preterm (< 32 weeks GA) and moderate to late preterm and term (≥ 32 weeks GA). Results: 125 of 3,277 patients developed cholestasis. Overall incidence of cholestasis was 4%. Incidence was 5 times higher in neonates < 32 weeks GA compared to neonates ≥ 32 weeks GA. Cholestasis was associated with parenteral nutrition in 91% of patients with GA < 32 weeks and 40% of patients with GA ≥ 32 weeks (p < 0.01). While ursodiol treatment was prescribed more to cholestatic neonates ≥ 32 weeks GA, fish oil lipid was administered more to neonates < 32 weeks GA, among patients receiving parenteral nutrition. Conclusions: Neonatal cholestasis was associated with two different clinical profiles based on GA. We recommend diagnostic tests and clinical management of neonatal cholestasis be adapted to GA. A GA-based approach to the evaluation of an infant with conjugated hyperbilirubinemia is proposed.

Problématique : Durant la période fœtale, le métabolisme global du fœtus fonctionne en hypoxie, ce qui limite la phosphorylation oxydative dans la mitochondrie, et par conséquent la production d’adénosine triphosphate (ATP). Ces conditions sont nécessaires pour le développement intra-utérin. Lors de la naissance, l’augmentation des concentrations d’oxygène et un stress oxydatif permettent une transition métabolique. Une charge oxydative supplémentaire en période néonatale pourrait perturber cette transition métabolique et causer des complications. La nutrition parentérale (NP) administrée aux nouveau-nés prématurés apporte un triple fardeau oxydatif : une exposition à des peroxydes oxydants autogénérés par l’interaction des composants de la NP, une carence en vitamine C (instable en solution), et une déficience en glutathion, vu la charge oxydative élevée. Cette charge oxydative excessive affecte l’homéostasie redox au foie et aux poumons, ainsi que le métabolisme énergétique hépatique, et ce, par des effets immédiats et à long-terme. La méthylation de l’ADN est un possible mécanisme qui explique les effets à long terme. Le but de ce travail était de caractériser l’impact à court- et long-terme de la NP néonatale sur l’homéostasie redox, la méthylation de l’ADN, et le métabolisme des glucides et lipides, en isolant chacun des facteurs nutritionnels. Méthodes : Des cochons d’Inde ont été divisés dans les groupes suivants 1) NP : nutrition intraveineuse complète ; 2) NP+ glutathion disulfure (GSSG) (6 ou 12µM- substrat pour la synthèse intra-cellulaire de glutathion); 3) Diète complète : nutrition orale complète 4) Diète déficiente en Vitamine C; 5) Diète déficiente en Cystéine; 6) Diète double déficiente; ou. À 1 semaine de vie, la moitié des animaux était sacrifié et l’autre moitié a commencé à manger une diète complète jusqu’à l’âge adulte. Résultats et discussion : Les animaux ayant reçu une NP néonatale ont un métabolisme énergétique permettant la synthèse de nicotinamide adénine dinucléotide phosphate (NADPH) par l’augmentation de l’activité de la glucokinase (captation de glucose), et diminution de celles de la phosphofructokinase-1 (PFK-1) (glycolyse) et acétyl-CoA-carboxylase-1 (ACC)(lipogenèse). À l’âge adulte, les animaux ont une diminution des niveaux de GSSG, indiquant un débalancement de l’homéostasie redox vers le côté réducteur programmé par la NP néonatale. L’activité augmentée de l’ACC suggère une tendance à accumuler les lipides au foie à la suite d’une diète riche en glucides. L’ajout de glutathion à la NP ne prévient pas ces perturbations, car les déficiences en glutathion et vitamine C jouent un rôle sur la modulation des niveaux protéiques de l’ACC. Les diètes néonatales déficientes en vitamine C et cystéine augmentent l’activité de la PFK-1. Cette augmentation se maintient jusqu’à l’âge adulte chez les mâles, mais pas chez les femelles. Les niveaux protéiques de la glucokinase et ACC sont diminués à 1 semaine, et ceux de l’ACC sont élevés à 3 mois dans les groupes ayant reçu une des diètes déficientes. Ces effets sont similaires à ceux trouvés dans les animaux nourris avec la NP, suggérant que la déficience de la NP en ces nutriments et non les peroxydes cause ces effets. Dans tous les groupes, un stress oxydatif a été démontré à 1 semaine de vie, soit par l’augmentation des niveaux de GSSG, ou la diminution du GSH. Cet effet est vrai pour le foie et le poumon. Une réponse de Nrf2 est observée aussi au foie, ce qui caractérise un niveau bas de stress oxydatif. La baisse de GSH pulmonaire chez les animaux déficients est secondaire à l’inhibition oxydative de la voie de transméthylation au foie. Une diminution des niveaux d’ARNm de glutathion réductase et glutarédoxine sont observées, ce qui favorise encore le stress oxydatif pulmonaire. À long terme, les effets sont les opposés, soit débalancement de l’homéostasie redox vers le côté réducteur au foie et poumon. La méthylation de l’ADN était diminuée au foie des animaux nouveau-nés recevant les diètes déficientes, mais aucun changement n’a été observé aux poumons. Cette diminution est en accord avec les hauts niveaux d’ARNm des gènes de la protéine régulatrice de la glucokinase, et AMPK. À long-terme, l’effet inverse est observé pour la méthylation de l’ADN Conclusion : La NP modifie le flot d’énergie au foie à 1 semaine visant favoriser le métabolisme redox en détriment du métabolisme énergétique. Cet effet semble créer une déficience énergétique fonctionnelle, qui se développe en une lipogenèse accrue en âge adulte. Cela peut représenter un exemple de la plasticité développementale. Bien qu’un stress oxydatif en âge néonatal ne soit pas létal, il affecte le métabolisme énergétique et redox à long-terme, probablement par la méthylation de l’ADN. Les résultats de ce travail démontrent que ces animaux adultes ont une capacité accrue d’entreposer de l’énergie, soit par une lipogenèse plus élevée, soit par une accumulation d’énergie redox (glutathion). Aucune maladie métabolique n’était observée chez les animaux, mais il est attendu à ce que ces animaux développent ces maladies plus facilement suite à l’exposition à des insultes (habitudes de vie malsaines, tabagisme, etc.). / Problematic: During the fetal period, the general metabolism works under hypoxia, limiting oxidative phosphorylation in mitochondria and adenine triphosphate (ATP) synthesis. These conditions are necessary for intrauterine development. After birth, the increasing oxygen concentrations and the associated oxidative stress induce a metabolic transition. An excessive oxidative load during the neonatal period could perturb this transition. Parenteral nutrition (PN) administered to premature newborns comes with a triple oxidative burden: contaminating peroxides generated in solution, vitamin C deficiency (unstable in solution), and glutathione deficiency (caused by the high oxidative load). This oxidative load affects redox homoeostasis in the liver and lungs, as well as energy metabolism in the liver. These effects are not only immediate, but they are also delayed. DNA methylation is a candidate mechanism explaining the long-term effects. The objective of this work was to characterize the short- and long-term impacts of neonatal PN over redox homoeostasis, DNA methylation and carbohydrate and lipid metabolism by isolating each of these factors. Methods: Six groups of three-day-old guinea pigs received for 4 days either: 1) Total PN; 2) PN+glutathione disulfide (GSSG) (6 or 12µM-anti-peroxide);3) Vitamin C deficient; 4) Cysteine deficient; 5) Double deficient; or 6) Complete diets. At 1 week of life, half of the animals were sacrificed, and the other half started eating nutritionally complete diets until adulthood. Results and discussion: NP animals had energy metabolism shifted favouring nicotinamide adenine dinucleotide phosphate (NADPH) synthesis, as evidenced by the increase in glucokinase activity (glucose trapping in hepatocytes) and decrease in phosphfuctokinase-1 (PFK-1) (glycolysis) and acetyl-CoA-carboxyalase-1 (ACC) (lipogenesis) activities. Adding GSSG to parenteral nutrition prevents these changes. During adulthood, ACC activity is increased, suggesting a tendency to accumulate lipids after a diet rich in carbohydrates. Adding GSSG to PN does not prevent these changes as they seem to be caused by the nutritional deficiencies in vitamin C and cysteine. Neonatal diets deficient in vitamin C and cysteine increase PFK-1 activity. This increase is maintained until adulthood in males but not in females. Protein levels of glucokinase and ACC are decreased at 1 week of life and ACC levels are increased at adulthood in deficient groups. These effects are like the ones observed in PN animals. In all groups, oxidative stress is demonstrated in 1-week-old animals, either by an increase in GSSG levels, or a decrease in GSH. This is true for the liver and lungs. An Nrf2 response is also observed in the liver, suggesting a low level of oxidative stress. The decrease in lung GSH is secondary to the oxidative inhibition of the transmethylation pathway in the liver. Decreased levels of glutathione reductase and glutaredoxin mRNA levels are observed in lungs, favouring pulmonary oxidative stress. At adulthood, an imbalance in redox homeostasis towards a reducing state is observed in lungs and liver. DNA methylation was decreased in the liver of deficient animals at 1-week, but no changes were observed in lungs. This decrease is in accordance with the decrease in mRNA levels of glucokinase regulatory protein and AMPK. At adulthood, the opposite effect was observed for DNA methylation. Conclusion: Parenteral nutrition alters the energy flow in the liver of 1-week-old animals, favouring redox metabolism over energy metabolism. This effect seems to create a phenotype of functional energy deficiency which translates into an increased lipogenesis at adult age. This may be an example of developmental plasticity. Although neonatal oxidative stress is not lethal, it affects energy and redox metabolism at adulthood, probably through DNA methylation. The presented results demonstrate these animals have an increased capacity of storing energy, either through increased lipogenesis, or by an increase in redox energy accumulation (glutathione). No metabolic disease was observed. Although it would be expected that these animals would develop these diseases more easily after exposure to insults, such as unhealthy lifestyle habits, smoking, and others.

No description available.